RPID files 8-K furnishing Q3 2025 results press release

Rhea-AI Filing Summary

Rapid Micro Biosystems (RPID) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.

The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing also includes Exhibit 104 for the cover page inline XBRL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001380106false00013801062025-11-072025-11-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 7, 2025

RAPID MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-40592			20-8121647
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
25 Hartwell Avenue, Lexington, MA						02421
(Address of principal executive offices)						(Zip Code)

978-349-3200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of each exchange on which registered

Class A Common Stock, $0.01 par value per share

RPID

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 7, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release of Rapid Micro Biosystems, Inc., dated November 7, 2025, related to its financial results for its third quarter ended September 30, 2025.
104						Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			RAPID MICRO BIOSYSTEMS, INC.
Date: November 7, 2025			By:			/s/ Sean Wirtjes
						Sean Wirtjes
						Chief Financial Officer

FAQ

What did Rapid Micro Biosystems (RPID) disclose in this 8-K?

The company announced it issued a press release with financial results for the quarter ended September 30, 2025, furnished under Item 2.02.

Which period do the results cover for RPID?

The results cover the third quarter ended September 30, 2025.

Where can I find the detailed results for RPID’s Q3 2025?

They are contained in Exhibit 99.1, a press release incorporated by reference.

Is the information considered filed or furnished?

It is furnished under Item 2.02 and not deemed filed under the Exchange Act.

What exhibits accompany this 8-K for RPID?

Exhibit 99.1 (press release for Q3 2025 results) and Exhibit 104 (cover page inline XBRL).

On which exchange does RPID trade and under what symbol?

Class A common stock trades on The Nasdaq Capital Market under the symbol RPID.